AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company’s history roots back to the year 1913 when Astra business was formed. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
94,300
Employees94,300
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
94,300
Employees94,300

AZN Key Statistics

Market cap
294.09B
Market cap294.09B
Price-Earnings ratio
30.86
Price-Earnings ratio30.86
Dividend yield
1.70%
Dividend yield1.70%
Average volume
14.25M
Average volume14.25M
High today
$192.79
High today$192.79
Low today
$188.47
Low today$188.47
Open price
$190.44
Open price$190.44
Volume
1.95M
Volume1.95M
52 Week high
$192.79
52 Week high$192.79
52 Week low
$30.62
52 Week low$30.62

Stock Snapshot

AstraZeneca(AZN) stock is priced at $189.68, giving the company a market capitalization of 294.09B. It carries a P/E multiple of 30.86 and pays a dividend yield of 1.7%.

On 2026-02-02, AstraZeneca(AZN) stock traded between a low of $188.47 and a high of $192.79. Shares are currently priced at $189.68, which is +0.6% above the low and -1.6% below the high.

AstraZeneca(AZN) shares are trading with a volume of 1.95M, against a daily average of 14.25M.

In the last year, AstraZeneca(AZN) shares hit a 52-week high of $192.79 and a 52-week low of $30.62.

In the last year, AstraZeneca(AZN) shares hit a 52-week high of $192.79 and a 52-week low of $30.62.

AZN News

TipRanks 2h
AstraZeneca rises 106.9%

AstraZeneca (AZN) is up 106.9%, or $99.16 to $191.93. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try...

TipRanks 3h
AstraZeneca Tests Next-Gen Cell Therapy in Multiple Sclerosis: What Investors Should Watch

AstraZeneca (AZN) announced an update on their ongoing clinical study. Study Overview AstraZeneca is running a Phase 1b trial titled “A Phase 1b, Open-label,...

TipRanks 4h
AstraZeneca Confirms Updated Share Capital and Voting Rights

AstraZeneca ( (GB:AZN) ) just unveiled an update. AstraZeneca has confirmed that, as of 31 January 2026, its issued share capital with voting rights stands at...

Analyst ratings

83%

of 30 ratings
Buy
83.3%
Hold
3.3%
Sell
13.3%

More AZN News

TipRanks 8h
AstraZeneca’s Imfinzi perioperative regimen recommended for approval in EU

AstraZeneca’s (AZN) Imfinzi in combination with standard-of-care FLOT chemotherapy has been recommended for approval in the European Union for the treatment of...

Yahoo Finance 4d
UK drugs giant AstraZeneca announces $15 bn investment in China - Yahoo Finance

...

UK drugs giant AstraZeneca announces $15 bn investment in China - Yahoo Finance

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.